Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5945_Библиотеки_им_академика_М_И_Перельмана
.pdf
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
286
36 Bols, M., López, Ó., and OrtegaCaballero, F. (2007). Glycosidase inhibitors:
structure, activity, synthesis, and medical relevance. In: Comprehensive
Glycoscience‐from Chemistry to Systems Biology (ed. J.P. Kamerling), 815–884.
Elsevier.
3 7 Conforti, I. and Marra, A. (2021). Organic & Biomolecular Chemistry 19: 5439–5475.
38 Merino, P., Delso, I., Marca, E. etal. (2009). Current Chemical Biology 3: 253–271.
39 Butters, T.D., Dwek, R.A., and Platt, F.M. (2005). Glycobiology 15: 43R–52R.
40 Compain, P. and Martin, O.R. (2003). Current Topics in Medicinal Chemistry 3:
541–560.
41 Butters, T.D., Dwek, R.A., and Platt, F.M. (2000). Chemical Reviews 100: 4683–4696.
42 Dorling, P.R., Huxtable, C.R., and Vogel, P. (1978). Neuropathology and Applied
Neurobiology 4: 285–295.
43 Molyneux, R.J. and James, L.F. (1982). Science 216: 190–191.
44 Cenci di Bello, I., Dorling, P., and Winchester, B. (1983). Biochemical Journal 215:
693–696.
45 Solomon, M. and Muro, S. (2017). Advanced Drug Delivery Reviews 118: 109–134.
46 Rodríguez, M.C., Ceaglio, N., Antuña, S. etal. (2019). Chapter2: Production of
therapeutic enzymes by lentivirus transgenesis. In: Therapeutic Enzymes: Function
and Clinical Implications, Advances in Experimental Medicine and Biology 1148 (ed.
N. Labrou), 25–54. Springer Nature Singapore Pte Ltd.
47 Oh, D.B. (2015). BMB Reports 48: 438–444.
48 Sharma, A., Vaghasiya, K., Ray, E., and Verma, R.K. (2018). Journal of Drug
Targeting 26: 208–221.
49 Cenci di Bello, I., Mann, D., Nash, R., and Winchester, B.G. (1988).
Castanospermineinduced deficiency of lysosomal βglucosidase: a model of
Gaucher’s disease in fibroblasts. In: Lipid Storage Disorders: Biological and Medical
Aspects (ed. R. Salvayre, L. DousteBlazy, and S. Gatt), 635–641. NewYork: Plenum.
50 Platt, F.M., Nieses, G.R., Reinkensmeir, G. etal. (1997). Science 276: 428–431.
51 Schiffmann, R., Fitzgibbon, E.J., Harris, C. etal. (2008). Annals of Neurology 64:
514–522.
52 Patterson, M.C., Vecchio, D., Prady, H. etal. (2006). Revista de Neurologia 43: 8.
53 Patterson, M.C., Vecchio, D., Prady, H. etal. (2007). Lancet Neurology 6: 765–772.
54 Walterfang, M., Chien, Y.H., Imrie, J. etal. (2012). Orphanet Journal of Rare
Diseases 7: 76–93.
55 Lyseng Williamson, K.A. (2014). Drugs 74: 61–74.
56 Coutinho, M.F., Santos, J.I., and Alves, S. (2016). International Journal of Molecular
Sciences 17: 1065–1087.
57 Winchester, B.G. (2009). Tetrahedron: Asymmetry 20: 645–651.
58 Fan, J.Q., Ishii, S., Asano, N., and Suzuki, Y. (1999). Nature Medicine 5: 112–115.
59 Pereira, D.M., Valentão, P., and Andrade, P.B. (2018). Chemical Science 9:
1740–1752.
60 Convertino, M., Das, J., and Dokholyan, N.V. (2016). ACS Chemical Biology 11:
1471–1489.
61 SánchezFernández, E.M., García Fernández, J.M., and Ortiz Mellet, C. (2016).
Chemical Communications 52: 5497–5515.

References
62 Fan, J.Q. (2008). Biological Chemistry 389: 1–11.
63 Gloster, T.M. and Vocadlo, D.J. (2012). Nature Chemical Biology 8: 683–694.
64 Stütz, A.E. and Wrodnigg, T.M. (2016). Advances in Carbohydrate Chemistry and
Biochemistry 73: 225–302.
65 Frustaci, A., Chimenti, C., Ricci, R. etal. (2001). The New England Journal of
Medicine 345: 25–32.
66 Tsukimura, T., Chiba, Y., Ohno, K. etal. (2011). Molecular Genetics and Metabolism
103: 26–32.
67 McCafferty, E.H. and Scott, L.J. (2019). Drugs 79: 543–554.
68 https://www.ema.europa.eu/en/medicines/human/EPAR/galafold (May 2022).
69 Moran, N. (2018). FDA approves Galafold, a triumph for amicus. Nature
Biotechnology 36: 913.
70 Sun, Y., Liou, B., Xu, Y.H. etal. (2012). The Journal of Biological Chemistry 287:
4275–4287.
71 Benito, J.M., García Fernández, J.M., and Mellet, C.O. (2011). Expert Opinion on
Therapeutic Patents 21: 885–903.
72 Dasgupta, N., Xu, Y.H., Li, R. etal. (2015). Human Molecular Genetics 24:
7031–7048.
73 Liguori, L., Monticelli, M., Allocca, M. etal. (2020). International Journal of
Molecular Sciences 21: 489–509.
74 Boyd, R.E., Benjamin, E.R., Xu, S. etal. (2016). Chapter15: Pharmacological
chaperones as potential therapeutics for lysosomal storage disorders: preclinical
research to clinical studies. In: Lysosome: Biology, Disease and Therapeutics (ed.
F.R. Maxfield, J.M. Willard, and S. Lu), 357–382. John Wiley & Sons, Inc.
75 MenaBarragán, T., Narita, A., Matias, D. etal. (2015). Angewandte Chemie,
International Edition 54: 11696–11700.
76 Castellan, T., Garcia, V., Rodriguez, F. etal. (2020). Organic & Biomolecular
Chemistry 18: 7852–7861.
77 Tran, M.L., Génisson, Y., Ballereau, S., and Dehoux, C. (2020). Molecules 25:
3145–3166.
78 Mohamed, F.E., AlGazali, L., AlJasmi, F., and Ali, B.R. (2017). Frontiers in
Pharmacology 8: 448.
79 Aymami, J., Barril, X., RodríguezPascau, L., and Martinell, M. (2013).
Pharmaceutical Patent Analyst 2: 109–124.
80 Neufeld, E. and Muenzer, J. (2001). The mucopolysaccharidoses. In: The Metabolic
and Molecular Bases of Inherited Diseases (ed. C. Scriver, A. Beaudet, W. Sly, and
D. Valle), 3421–3452. NewYork: McGrawHill.
81 Sawamoto, K., Stapleton, M., AlmécigaDíaz, C.J. etal. (2019). Drugs 79: 1103–1134.
82 Hobbs, J.R. (1981). Lancet 2: 735–739.
83 Scarpa, M., Orchard, P.J., Schulzd, A. etal. (2017). Molecular Genetics and
Metabolism 122: 25–34.
84 Giugliani, R., Federhen, A., Vairo, F. etal. (2016). Expert Opinion on Emerging
Drugs 21: 9–26.
85 Giugliani, R., Dalla Corte, A., Poswar, F. etal. (2018). Expert Opinion on Orphan
Drugs 6: 403–411.
287

Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
288
86 Schuh, R.S., Baldo, G., and Teixeira, H.F. (2016). Expert Opinion on Drug Delivery
13: 1709–1718.
87 Hoshina, H., Shimada, Y., Higuchi, T. etal. (2018). Molecular Genetics and
Metabolism 123: 118–122.
88 Zhu, S., Jagadeesh, Y., Tuan Tran, A. etal. (2021). Chemistry‐ A European Journal
44: 11291–11297.
89 Feldhammer, M., Durand, S., and Pshezhetsky, A.V. (2009). PLoS One 4: e7434.
90 AlmecigaDiaz, C.J., Hidalgo, O.A., OlarteAvellaneda, S. etal. (2019). Journal of
Medicinal Chemistry 62: 6175–6189.
91 Del OlarteAvellaneda, J.C., Castillo, A.F., RojasRodriguez, O. etal. (2020). ACS
Medicinal Chemistry Letters 11: 1377–1385.
92 Matassini, C., Parmeggiani, C., Cardona, F., and Goti, A. (2016). Tetrahedron
Letters 57: 5407–5415.
93 Matassini, C., D’Adamio, G., Vanni, C. etal. (2019). European Journal of Organic
Chemistry 4897–4905.
94 D’Adamio, G., Matassini, C., Parmeggiani, C. etal. (2016). RSC Advances 6:
64847–64851.
95 Matassini, C., Vanni, C., Goti, A. etal. (2018). Organic & Biomolecular Chemistry
16: 8604–8612.
96 van der Tol, L., Smid, B.E., Poorthuis, B.J. etal. (2014). Journal of Medical Genetics
51: 1–9.
97 Wang, H., Shen, Y., Zhao, L., and Ye, Y. (2021). Current Medicinal Chemistry 28:
628–643.
98 van der Veen, S.J., Hollak, C.E.M., van Kuilenburg, A.B.P., and Langeveld,
M. (2020). Journal of Inherited Metabolic Disease 43: 908–921.
99 Arends, M., Hollak, C.E.M., and Biegstraaten, M. (2015). Orphanet Journal of Rare
Diseases 10: 77.
100 Weidemann, F., Niemann, M., Stork, S. etal. (2013). Journal of Internal Medicine
274: 331–341.
101 Rombach, S.M., Smid, B.E., Linthorst, G.E. etal. (2014). Journal of Inherited
Metabolic Disease 37: 341–352.
102 Abasolo, I., SerasFranzoso, J., MoltóAbad, M. etal. (2021). WIREs Nanomedicine
and Nanobiotechnology 13: e1684.
103 Guérard, N., Oder, D., Nordbeck, P. etal. (2018). Clinical Pharmacology and
Therapeutics 103: 703–711.
104 Welford, R., Mühlemann, A., Garzotti, M. etal. (2018). Human Molecular Genetics
27: 3392–3403.
105 Benjamin, E.R., Della Valle, M.C., Wu, X. etal. (2017). Genetics in Medicine 4:
430–438.
106 AguilarMoncayo, M., Takai, T., Higaki, K. etal. (2012). Chemical Communications
48: 6514–6516.
107 Jenkinson, S.F., Fleet, G.W.J., Nash, R.J. etal. (2011). Organic Letters 13:
4064–4067.
108 Yu, Y., MenaBarragán, T., Higaki, K. etal. (2014). ACS Chemical Biology 9:
1460–1469.

References
109 Kato, A., Yamashita, Y., Nakagawa, S. etal. (2010). Bioorganic & Medicinal
Chemistry 18: 3790–3794.
110 MartínezBailén, M., Carmona, A.T., Cardona, F. etal. (2020). European Journal
of Medicinal Chemistry 192: 112173.
111 Cheng, W.C., Wang, J.H., Li, H.Y. etal. (2016). European Journal of Medicinal
Chemistry 123: 14–20.
112 Li, H.Y., Lee, J.D., Chen, C.W. etal. (2018). European Journal of Medicinal
Chemistry 144: 626–634.
113 Johnson, F.K., Mudd, P.N.J., DiMino, T. etal. (2015). Clinical Pharmacology in
Drug Development 4: 256–261.
114 Ishii, S., Chang, H.H., Yoshioka, H. etal. (2009). The Journal of Pharmacology and
Experimental Therapeutics 328: 723–731.
115 Gaggl, M. and SunderPlassmann, G. (2016). Nature Reviews. Nephrology 12:
653–654.
116 Germain, D.P., Giugliani, R., Hughes, D.A. etal. (2012). Orphanet Journal of Rare
Diseases 7: 91.
117 Citro, V., PeñaGarcía, J., denHaan, H. etal. (2016). PLoS One 11: e0165463.
118 Khanna, R., Valenzano, K.J., and Fowles, S.E. (2014). PCT International
Application WO2014014938A1.
119 Grabowski, G.A. (ed.) (2013). Advances in Gaucher Disease: Basic and Clinical
Perspectives. Unitec House, 2 Albert Place, London N3 1QB, UK: Future
Medicine Ltd.
120 Human Gene Mutation Database (HGMD). http://www.hgmd.cf.ac.uk/ac/index
.php (May 2023).
121 Ryan, E., Seehra, G., Sharma, P., and Sidransky, E. (2019). Current Opinion in
Neurology 32: 589–596.
122 Zimran, A. and Elstein, D. (2014). Pediatric Endocrinology Reviews 12: 82–87.
123 Mistry, P.K., Lukina, E., Ben Turkia, H. etal. (2017). American Journal of
Hematology 92: 1170–1176.
124 Kuriyama, C., Kamiyama, O., Ikeda, K. etal. (2008). Bioorganic & Medicinal
Chemistry 16: 7330–7336.
125 Chang, H., Asano, N., Ishii, S. etal. (2006). The FEBS Journal 273: 4082–4092.
126 Zhu, X., Sheth, K.A., Li, S. etal. (2005). Angewandte Chemie (International Ed. in
English) 44: 7450–7453.
127 Fan, J.Q., Zhu, X., and Sheth, K., WO2005046612, 2005 and
US20100189708, 2010.
128 Sawker, A.R., Cheng, W.C., Beutler, E. etal. (2002). Proceedings of the National
Academy of Sciences 99: 15428–15433.
129 Brumshtein, B., Greenblatt, H.M., Butters, T.D. etal. (2007). The Journal of
Biological Chemistry 282: 29052–29058.
130 Compain, P., Martin, O.R., Boucheron, C. etal. (2006). ChemBioChem 7:
1356–1359.
131 Luan, Z., Higaki, K., AguilarMoncayo, M. etal. (2009). ChemBioChem 10:
2780–2792.
289

Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
290
132 Kato, A., Nakagome, I., Sato, K. etal. (2016). Organic & Biomolecular Chemistry
14: 1039–1048.
133 Castilla, J., Rísquez, R., Higaki, K. etal. (2015). European Journal of Medicinal
Chemistry 90: 258–266.
134 Joosten, A., Decroocq, C., de Sousa, J. etal. (2014). ChemBioChem 15: 309–319.
135 Clemente, F., Matassini, C., Goti, A. etal. (2019). Chemistry Letters 10: 621–626.
136 Clemente, F., Matassini, C., Faggi, C. etal. (2020). Bioorganic Chemistry 98:
103740–103763.
137 GarciaMoreno, M.I., de la Mata, M., SánchezFernández, E.M. etal. (2017).
Journal of Medicinal Chemistry 60: 1829–1842.
138 https://clinicaltrials.gov/ct2/show/NCT03950050 (February 2023).
139 SerraVinardell, J., Díaz, L., Casas, J. etal. (2014). ChemMedChem 9: 1744–1754.
140 Shen, J.S., Edwards, N.J., Hong, Y.B., and Murray, G.J. (2008). Biochemical and
Biophysical Research Communications 369: 1071–1075.
141 Kornhaber, G.J., Tropak, M.B., Maegawa, G.H. etal. (2008). ChemBioChem 9:
2643–2649.
142 Vanier, M.T. (2013). Chapter176: Niemann–Pick diseases. In: Handbook of
Clinical Neurology, vol. 113 (3rd series) Pediatric Neurology Part III, (ed. O. Dulac,
M. Lassonde, and H.B. Sarnat), 1717–1721. Elsevier.
143 Pineda, M., Walterfang, M., and Patterson, M.C. (2018). Orphanet Journal of Rare
Diseases 13: 140–161.
144 Schuchman, E.H. and Desnick, R.J. (2017). Molecular Genetics and Metabolism
120: 27–33.
145 Suzuki, Y., Oshima, A., and Namba, E. (2001). βGalactosidase deficiency
(βgalactosidosis) GM1gangliosidosis and Morquio B disease. In: The Metabolic
and Molecular Bases of Inherited Disease (ed. C.R. Scriver, A.L. Beaudet, W.S. Sly,
and D. Valle), 3775–3809. NewYork: McGrawHill.
146 BrunettiPierri, N. and Scaglia, F. (2008). Molecular Genetics and Metabolism 94:
391–396.
147 Prat, C., Lemaire, O., Bret, J. etal. (2008). Joint, Bone, Spine 75: 495–498.
148 Tominaga, L., Ogawa, Y., Taniguchi, M. etal. (2001). Brain & Development 23:
284–287.
149 Rigat, B.A., Tropak, M.B., Buttner, J. etal. (2012). Molecular Genetics and
Metabolism 107: 203–212.
150 Takai, T., Higaki, K., AguilarMoncayo, M. etal. (2013). Molecular Therapy 21:
526–532.
151 Front, S., BielaBanas, A., Burda, P. etal. (2017). European Journal of Medicinal
Chemistry 126: 160–170.
152 Front, S., Almeida, S., Zoete, V. etal. (2018). Bioorganic & Medicinal Chemistry 26:
5462–5469.
153 Siriwardena, A., Sonawane, D.P., Bande, O.P. etal. (2014). The Journal of Organic
Chemistry 79: 4398–4404.
154 Matsuda, J., Suzuki, O., Oshima, A. etal. (2003). Proc. Natl. Acad. Sci. USA 100:
15912–15917.

References
155 Fantur, K., Hofer, D., Schitter, G. etal. (2010). Molecular Genetics and Metabolism
100: 262–268.
156 Schalli, M., Tysoe, C., Fischer, R. etal. (2017). Bioorganic & Medicinal Chemistry
Letters 27: 3431–3435.
157 Sandho, K. and Harzer, K. (2013). The Journal of Neuroscience 33: 10195–10208.
158 Leal, A.F., BenincoreFlórez, E., SolanoGalarza, D. etal. (2020). International
Journal of Molecular Sciences 21: 6213–6240.
159 Jeyakumar, M., Butters, T.D., CortinaBorja, M. etal. (1999). Proceedings of the
National Academy of Sciences of the United States of America 96: 6388–6393.
160 Shapiro, B.E., Pastores, G.M., Gianutsos, J. etal. (2009). Genetics in Medicine 11:
425–433.
161 Tropak, M.B., Reid, S.P., Guiral, M. etal. (2004). Biological Chemistry 279:
13478–13487.
162 Rountree, J.S.S., Butters, T.D., Wormald, M.R. etal. (2009). ChemMedChem 4:
378–392.
163 Kato, A., Nakagome, I., Nakagawa, S. etal. (2017). Organic & Biomolecular
Chemistry 15: 9297–9304.
164 Maegawa, G.H., Tropak, M., Buttner, J. etal. (2007). The Journal of Biological
Chemistry 282: 9150–9161.
165 Bateman, K.S., Cherney, M.M., Mahuran, D.J. etal. (2011). Journal of Medicinal
Chemistry 54: 1421–1429.
166 Chiricozzi, E., Niemir, N., Aureli, M. etal. (2014). Molecular Neurobiology 50:
159–167.
167 Clarke, J.T., Mahuran, D.J., Sathe, S. etal. (2011). Molecular Genetics and
Metabolism 102: 6–12.
168 Osher, E., FattalValevski, A., Sagie, L. etal. (2015). Orphanet Journal of Rare
Diseases 10: 1–7.
169 Mikulka, C.R. and Sands, M.S. (2016). Journal of Neuroscience Research 94:
1126–1137.
170 Bradbury, A.M., Bongarzone, E.R., and Sands, M.S. (2021). Neuroscience Letters
752: 135841–135841.
171 Hill, C.H., Viuff, A.H., Spratley, S.J. etal. (2015). Azasugar inhibitors as
pharmacological chaperones for Krabbe disease. Chemical Science 6: 3075–3086.
172 Viuff, A., Salamone, S., McLoughlin, J. etal. (2021). The bicyclic form of galacto
noeurostegine is a potent inhibitor of βgalactocerebrosidase. ACS Medicinal
Chemistry Letters 12: 56–59.
173 BielaBanaś, F., Oulaïdi, S., Front, E. etal. (2014). Martin iminosugarbased
galactoside mimics as inhibitors of galactocerebrosidase: SAR studies and
comparison with other lysosomal galactosidases. ChemMedChem 9: 2647–2652.
174 Do, H.V., Khanna, R., and Gotschall, R. (2019). Annals of Translational Medicine
7: 291–306.
175 Meena, N.K. and Raben, N. (2020). Biomolecules 10: 1339–1378.
176 Flanagan, J.J., Rossi, B., Tang, K. etal. (2009). Human Mutation 30: 1683–1692.
177 Parenti, G., Zuppaldi, A., Pittis, M.G. etal. (2007). Molecular Therapy 15: 508–514.
291

Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
292
178 D’Alonzo, D., De Fenza, M., Porto, C. etal. (2017). Journal of Medicinal Chemistry
60: 9462–9469.
179 Khanna, R., Jr, A.C., Powe, Y. etal. (2014). PLoS One 9: e102092.
180 Kishnani, P., Tarnopolsky, M., Roberts, M. etal. (2017). Duvoglustat HCl increases
systemic and tissue exposure of active acid α glucosidase in pompe patients
coadministered with alglucosidaseα. Molecular Therapy 25: 1199–1208.
181 Porto, C., Cardone, M., Fontana, F. etal. (2009). Molecular Therapy 17: 964–971.
182 Parenti, G., Fecarotta, S., la Marca, G. etal. (2014). Molecular Therapy 22:
2004–2012.
183 Stepien, K.M., Ciara, E., and JezelaStanek, A. (2020). Genes 11: 1383–1406.
184 Taylor, R.M., Farrow, B.R., and Stewart, G.J. (1992). American Journal of Medical
Genetics 42: 628–632.
185 Taylor, R.M., Farrow, B.R., Stewart, G.J. etal. (1988). Transplantation Proceedings
20: 89–93.
186 Vellodi, A., Cragg, H., Winchester, B. etal. (1995). Bone Marrow Transplantation
15: 153–158.
187 Miano, M., Lanino, E., Gatti, R. etal. (2001). Bone Marrow Transplantation 27:
747–751.
188 Gupta, A., Lund, T.C., Anderson, N. etal. (2019). Molecular Genetics and
Metabolism 126: S66.
189 MorenoClavijo, E., Carmona, A.T., MorenoVargas, A.J. etal. (2011). Chimia
65: 40–44.
190 MorenoClavijo, E., Carmona, A.T., MorenoVargas, A.J. etal. (2011). Current
Organic Synthesis 8: 102–133.
191 Malm, D. and Nilssen, O. (2008). Orphanet Journal of Rare Diseases 3: 1–21.
192 Desnick, R.J., Sharp, H.L., Grabowski, G.A. etal. (1976). Pediatric Research 10:
985–996.
193 Autio, S., Louhimo, T., and Helenius, M. (1982). Annals of Clinical Research
14: 93–97.
194 Grewal, S.S., Shapiro, E.G., Krivit, W. etal. (2004). The Journal of Pediatrics 144:
569–573.
195 Yesilipek, A.M., Akcan, M., Karuso, G. etal. (2012). Pediatric Transplantation 16:
779–782.
196 Mynarek, M., Tolar, J., Albert, M.H. etal. (2012). Bone Marrow Transplantation 47:
352–359.
197 RísquezCuadro, R., Matsumoto, R., OrtegaCaballero, F. etal. (2019). Journal of
Medicinal Chemistry 62: 5832–5843.

10
Carbohydrates and Carbohydrate-Based Therapeutics
in Alzheimer’s Disease
Ana M. Matos, João Barros and Amélia P. Rauter
Universidade de Lisboa, Centro de Química Estrutural, Institute of Molecular Sciences, Faculdade de Ciências,
Department of Chemistry and Biochemistry, Ed. C8, Piso 5, Campo Grande, Lisboa, 1749-016, Portugal
10.1 Introduction
Carbohydrates, the most abundant organic compounds in nature, play unique roles
in health and disease. The complex glycans displayed on the cell surface facing the
extracellular space are the key molecules for cell recognition and adhesion in signaling pathways and in cell–pathogen interactions[1, 2]. Carbohydrates also trigger
immune responses[3–5], and modulate key biological processes in neurodegeneration, namely those related to the O-GlcNAc modification (also known as
O-GlcNAcylation) of serine (Ser) and threonine (Thr) protein residues in the brain,
the dysregulation of which is associated with neurodegenerative diseases [6, 7].
Alzheimer’s disease (AD) is the most common one, affecting 60% of the over 50 million people with dementia in 2020, a number expected to double every two years,
reaching 82 million in 2030 and 152 million in 2050[8]. AD is a chronic and progressive disease, resulting from an irreversible degeneration of the brain that causes
cognitive impairment, dementia, and ultimately results in death, as no efficient
therapeutics are known to control the progression of this pathology. This protein
misfolding disease is associated with the formation of soluble Aβ1–42 toxic small
oligomers, derived from abnormal cleavage of β-amyloid precursor protein (APP).
Their aggregation leads to the formation of fibrils, which give rise to extracellular
deposits, the senile plaques[9]. Another AD neuropathological hallmark consists of
intracellular neurofibrillary tangles (NFTs) formation due to altered kinase and
phosphatase activities, leading to hyperphosphorylation of the Tau protein. This is
followed by the aggregation of hyperphosphorylated Tau into paired helical filaments and, finally, into NFTs. The aggregation events and associated aggregation
stress leads to cell apoptosis[9, 10] (Figure10.1).
293
Carbohydrate-Based Therapeutics, First Edition. Edited by Roberto Adamo and Luigi Lay.
© 2024 WILEY-VCH GmbH. Published 2024 by WILEY-VCH GmbH.

10 Carbohydrates and Carbohydrate-Based Therapeutics in Alzheimer’s Disease
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
294
Healthy Neuron
Figure10.1 Healthy neuron vs. neuron after degeneration. Source: Adapted from
Demetrius etal.[9].
AD Neuron
Neurofibrillary tangles
(hyperphosphorylated tau)
Amyloid aggregates
Disease progression
Moreover, the cellular prion protein (PrPC), located in the neuronal cell surface,
is a high-affinity binding partner of Aβ oligomers (Aβos) and promotes the activation of Fyn kinase, triggering a cell signaling pathway that culminates in Tau
hyperphosphorylation[11]. Accordingly, Fyn activity increases in AD brain when
C
neurons are exposed to Aβo, via PrP
[12, 13]. Interestingly, prion protein misfolding also promotes prion amyloid formation. Its conformational transition from the
α-helix-rich cellular form into the mainly β-sheet containing counterpart initiates
an “autocatalytic” reaction that leads to the accumulation of amyloid fibrils
Sc
) in the central nervous system (CNS), leading to neurodegeneration. This
(PrP
amyloidogenic process is, among other factors, O-glycosyl dependent and can be
triggered or prevented by changing the sugar residue attached to Ser/Thr in the
PrP core[14].
AD epidemiological data, associated with its devastating nature, unsuccessful
treatment options, and high socio-economic impact are challenging for the
research of new therapeutics. In 2015, a review on carbohydrates and glycomimetics in AD diagnosis and therapeutics was published[15], covering molecules acting on Aβ amyloid events, namely glycosides containing terpenes, phenolics,
peptidomimetics, and metal-ion chelators, free and protected sugars, cyclitols and
glycosaminoglycans (GAGs). Carbohydrate-based molecules targeting the cholinergic system were also reviewed[16], namely the acetylcholinesterase (AChE) and
butyrrylcholinesterase (BChE) inhibitors, aiming to increase levels of the neurotransmitter acetylcholine (ACh) in the brain of AD patients. More recently, carbohydratepeptide conjugates were also reviewed as amyloidogenic aggregation
inhibitors[17].

In this chapter, we focus on the investigation carried out to uncover the role of
carbohydrates in AD and approaches toward carbohydrate-based therapeutics.
Dysregulation of O-GlcNAcylation in intracellular proteins is associated with neurodegenerative diseases, including AD, for which O-GlcNAc cycling is considered a
therapeutic target against the formation of amyloid plaques and NFTs . Patients
with AD have O-GlcNAc levels 50% lower than normal individuals, and efforts
toward the discovery of efficient carbohydrate-based therapeutics to control these
levels by inhibition of the O-GlcNAc hydrolase enzyme, O-GlcNAcase (OGA), are
here reviewed. Synthesis and bioactivity of the most promising classes of inhibitors
are presented, namely carbohydrate-based thiazolines, 2-acetamido-2-deoxy-glucono-1,5-lactone O-(phenylcarbamoyl)oxime (PUGNAc), and GlcNAc statins.
The role of GalNAc in neurodegeneration is also revised herein, highlighting
reports that show the importance of GalNAc levels in APP to control Aβ production
and the significance of GalNAc residues in chondroitin sulfate proteoglycans (PGs)
that play a role in regulating the trophic microenvironment of neurons. Moreover,
GalNAc containing oligosaccharides and chitosan (CTS) oligosaccharides have neurodegenerative effects and are also covered in this chapter.
AD is a multifactorial disease, with the cholinergic system of AD patients being
severely affected and represent a therapeutic target. ACh is a major neurotransmitter in the brain and AD patients have low levels of ACh, emerging the inhibition of
cholinesterases (ChEs), enzymes that split ACh into choline and acetate, as a promising option to treat AD. The drugs rivastigmine, galantamine, and donepezil are
clinically in use and act as ChE inhibitors. However, they are not efficient to control
disease progression and have side effects, such as convulsions, severe nausea, stomach cramps, vomiting, irregular breathing, confusion, muscle cramps, and muscle
weakness, among others[18, 19]. New directions in anticholinesterase drug development are encouraging and the latest findings on carbohydrate-based ChE inhibitors are also covered.
Finally, our latest discoveries on carbohydrate-based inhibitors of Fyn kinase, Aβ
aggregation, Aβ and prion binding, and of the oxidative stress-induced neurotoxicity are also disclosed. This chapter ends by giving an overview about carbohydrate–
protein interactions as potential targets for AD drug discovery.
29510.2 O-GlcNAc Transferase (OGT) and O-GlcNAc Hydrolase (OGA) in Neurodegeneration
10.2 O-GlcNAc Transferase (OGT) and O-GlcNAc
Hydrolase (OGA) in Neurodegeneration
The modification of the hydroxy group of Ser and Thr residues to install an O-(2acetamido-β--glucopyranosyl, O-GlcNAc) functionality (a process termed
O-GlcNAcylation) is an essential mechanism that takes place in cell cycle and metabolic processes on nuclear, cytoplasmic, and mitochondrial proteins. It is achieved
enzymatically by O-GlcNAc transferase (OGT), which transfers O-GlcNAc from uri-
dine diphosphate (UDP)-GlcNAc donor to Ser and Thr residues, while the enzymatic hydrolysis to remove the glycan and unveil the free hydroxy group is carried
out by OGA (Figure10.2), a member of the glycoside hydrolase family 84(GH84)of
Соседние файлы в папке Библиотека им академика М.И. Перельмана
